All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAR439859
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Preclinical data for Sanofi's investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research (AACR) Virtual Annual Meeting II on June 22-24.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAR439859
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
The four areas of strategic focus within oncology, including multiple myeloma, skin, lung, and breast cancers. Sanofi’s four anchor oncology treatments include Sarclisa® (isatuximab-irfc) and Libtayo® (cemiplimab-nwlc), and the pipeline programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lanreotide
Therapeutic Area: Oncology Product Name: Somatuline
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: IPH4102
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
The FDA decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the lacutamab clinical development program, including the TELLOMAK trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Darolutamide significantly reduced risk of death by 31% in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedopi,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 12, 2020
Details:
Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tumor infiltrating lymphocytes
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Iovance Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
Details:
Iovance Biotherapeutics will use TALEN® Technology from Cellectis to develop Gene-Edited TIL that have been genetically edited to create more potent cancer therapeutics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Details:
Innate Pharma will take the operational measures to reactivate the lacutamab TELLOMAK trial in Sézary syndrome and MF in France and UK, where regulatory agencies have authorized it.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
Details:
Innate Pharma decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
